2025 North America Anti-Obesity Drugs Market Revenue Opportunities Report
Description
The 2025 North America Anti-Obesity Drugs Market Revenue Opportunities Report features 1) market size data for the region or country, 2) annual market growth rates, 3) the market's impact on related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing, 4) Total Addressable Market (TOM) for the four largest market players, 5) Serviceable Addressable Market (SAM), and 6) Serviceable Obtainable Market (SOM)(Wharry Sharpe Research)
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Anti-Obesity Drugs Market by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in the North American anti-obesity drugs market are Novo Nordisk, Eli Lilly, Pfizer, and GlaxoSmithKline (GSK). Novo Nordisk leads significantly with its semaglutide-based drugs Wegovy and Ozempic, which are approved for chronic weight management and have strong sales in the U.S. market. Eli Lilly is a close competitor, offering tirzepatide-based drugs Mounjaro and Zepbound, which have shown superior weight-loss efficacy and are projected to surpass Novo Nordisk's sales by 2026. Pfizer also remains a key player, contributing to innovation and extensive clinical trials in the region. GSK has a notable presence with its over-the-counter anti-obesity drug Alli, enhancing accessibility for consumers.
These companies benefit from North America's high obesity rates and well-developed healthcare systems. The U.S. market dominance stems from strong regulatory approvals, extensive R&D, and distribution networks. Novo Nordisk and Eli Lilly drive the market through prescription drugs with demonstrated efficacy, while GSK and Pfizer diversify treatment options including OTC availability and lipase inhibitors like Orlistat marketed under Alli and Xenical. These factors combined with rising health awareness and government initiatives sustain growth, with North America holding over 65% of the global anti-obesity drug market share in 2023.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Anti-Obesity Drugs Market by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in the North American anti-obesity drugs market are Novo Nordisk, Eli Lilly, Pfizer, and GlaxoSmithKline (GSK). Novo Nordisk leads significantly with its semaglutide-based drugs Wegovy and Ozempic, which are approved for chronic weight management and have strong sales in the U.S. market. Eli Lilly is a close competitor, offering tirzepatide-based drugs Mounjaro and Zepbound, which have shown superior weight-loss efficacy and are projected to surpass Novo Nordisk's sales by 2026. Pfizer also remains a key player, contributing to innovation and extensive clinical trials in the region. GSK has a notable presence with its over-the-counter anti-obesity drug Alli, enhancing accessibility for consumers.
These companies benefit from North America's high obesity rates and well-developed healthcare systems. The U.S. market dominance stems from strong regulatory approvals, extensive R&D, and distribution networks. Novo Nordisk and Eli Lilly drive the market through prescription drugs with demonstrated efficacy, while GSK and Pfizer diversify treatment options including OTC availability and lipase inhibitors like Orlistat marketed under Alli and Xenical. These factors combined with rising health awareness and government initiatives sustain growth, with North America holding over 65% of the global anti-obesity drug market share in 2023.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
Table of Contents
51 Pages
- A. Definitions
- A1. Market Definition
- A2. Market Segmentation
- A3. Industry Opportunities-Industry1
- A4. Industry Opportunities-Industry2
- A5. Industry Opportunities-Industry3
- B. Total Addressable Market (TAM)
- B1. TAM-Player 1/4
- B2. TAM-Player 2/4
- B3. TAM-Player 3/4
- B4. TAM-Player 4/4
- C. Serviceable Addressable Market (SAM)
- C1. SAM-Player 1/4
- C2. SAM-Player 2/4
- C3. SAM-Player 3/4
- C4. SAM-Player 4/4
- D. Serviceable Obtainable Market (SOM)
- D1. SOM-Player 1/4
- D2. SOM-Player 2/4
- D3. SOM-Player 3/4
- D4. SOM-Player 4/4
- E. Appendix
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
